

## Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

### Stock Quote


ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$8.15</b>
Change (%)	-0.1 (1.21%)
Volume	148,305

Data as of May 25, 2018 4:00 p.m. ET

Minimum 20 minute delay

[Refresh quote](#)

### Stock Chart



## Press Releases

May 10, 2018

[Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference](#)

May 02, 2018

[Aduro Biotech Reports First Quarter 2018 Financial Results](#)

## Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters